Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03860987|
Recruitment Status : Recruiting
First Posted : March 4, 2019
Last Update Posted : January 26, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Prostate cancer is a common cancer among men. There are several ways to treat it, including hormone blocking drugs, radiation therapy, and surgery. Researchers want to combine abiraterone and enzalutamide to see if there is a better way to treat prostate cancer. They also want to study a new radiotracer called 18F-DCFPyL, with the help of a scan called positron emission tomography/computed tomography (PET/CT) to see if there is a better way to detect prostate cancer.
To develop improved techniques to localize and detect prostate cancer; and to develop new ways to treat prostate cancer
Men ages 18 and older with prostate cancer that has not spread to other parts of the body
- Participants will have a medical evaluation to determine eligibility for the study.
- Participants will take three different medications daily by mouth and receive two injections during the course of the study.
- Participants will have a medical evaluation monthly (for 6 months) while taking the medications.
- Participants will have prostate MRI and PET/CT scans before treatment, 2 months after starting treatment and again before surgery. The radiotracer will be given by injection about 2 hours before the whole-body scan. The PET/CT scan itself is about an hour.
- Participants may be asked to do a biopsy before treatment and 2 months after starting treatment.
- Participants will have a full medical evaluation before surgery to remove their prostate.
- Participants will have a follow-up visit 3 months after surgery and then as needed.
- Participants will be contacted once a year for their PSA and testosterone levels for 5 years...
|Condition or disease||Intervention/treatment||Phase|
|Castrate Sensitive Prostate Cancer||Drug: goserelin Drug: Enzalutamide Drug: Abiraterone Drug: 18F-DCFPyL Drug: Prednisone Procedure: Radical Prostatectomy||Phase 2|
- Most men diagnosed with prostate cancer will present with intermediate or high-risk disease, and many develop castrate resistant prostate cancer (CRPC) as curative strategies are often unsuccessful
- Treatment options typically involve radical prostatectomy (RP) or radiation therapy (RT) in combination with androgen deprivation therapy (ADT)
- PET imaging based on prostate specific membrane antigen (PSMA), including use of the radiotracer DCFPyL, which binds PSMA, has emerged as a sensitive modality to detect localized and metastatic prostate cancer
- It is unknown how androgen-targeted therapy affects expression of the androgen- regulated PSMA gene, FOLH1, and 18F -DCFPyL-PET/CT sensitivity; and, the correlation between response on 18F -DCFPyL-PET/CT imaging and clinical response needs further evaluation
- The use of highly effective androgen pathway inhibitors enzalutamide and abiraterone offers an opportunity to understand the characteristics of 18F -DCFPyL-PET imaging during treatment while potentially improving the cure rate of men with potentially lethal localized prostate cancer
- There remains a great need for improved techniques to determine mechanisms of treatment response and resistance
- To test the feasibility of 18F -DCFPyL-PET/CT for the localization of prostate cancer before, during, and after pre-operative treatment with ADT, enzalutamide, and abiraterone/prednisone in patients negative for metastatic disease
- Pathologic diagnosis of castration-sensitive prostate cancer with intermediate- or high- risk features and no evidence of metastases beyond N1 on conventional imaging
- Candidates for radical prostatectomy
- Testosterone levels greater than or equal to 100 ng/dL
- ECOG PS 0-1
- Men age greater than or equal to 18 years
- Patients will be treated with ADT, enzalutamide, and abiraterone/prednisone for 6 months, followed by standard of care radical prostatectomy (RP)
- 18F-DCFPyL-PET/CT and mpMRI scans prior to treatment, during months 3-5 and after 6 months of treatment
- Prostate tumor biopsy (MR/US-guided) samples for research analyses at baseline and after mid-treatment imaging (post-month 2)
- It is anticipated that approximately 1.5 to 2 years may be required for accrual of up to 25 evaluable subjects.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer|
|Actual Study Start Date :||April 30, 2019|
|Estimated Primary Completion Date :||August 31, 2025|
|Estimated Study Completion Date :||August 1, 2028|
Goserelin will be administered SC at 10.8 mg every 12 weeks
Enzalutamide will be given orally at 160mg once daily
Abiraterone will be taken orally at 1000 mg once daily
18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
Procedure: Radical Prostatectomy
- disease status [ Time Frame: 2 months ]The primary endpoint will be the disease status after completion of treatment relative to PSMA-PET imaging findings at 2 months
- pathological complete response rate [ Time Frame: 5 years ]Evaluate the pathological complete response rate after neoadjuvant treatment with ADT, enzalutamide, and abiraterone/prednisone
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Patients must have histologically or cytologically confirmed prostate cancer confirmed by the Laboratory of Pathology, NCI, OR documented histopathological confirmation of prostate cancer from a CLIA-certified laboratory.
Must have previously untreated (with definitive therapy ie: surgery, systemic treatment or radiation therapy) prostate cancer with intermediate or high risk features defined as:
Intermediate risk (patient must have at least one of the features listed below):
- PSA level is between 10 and 20 ng/ml,
- Gleason score is 7, OR
- Stage T2b or T2c,
High risk (patient must have at least one of the features listed below):
- PSA > 20 at the time of diagnosis,
- Gleason 8 or higher,
- Seminal vesicle involvement,
- Possible (on MRI) extra-capsular extension (T3 disease), OR
- Clinical stage T4
- Patients must be eligible for and must be planning to undergo radical prostatectomy
- Patients must have testosterone levels greater than or equal to 100 ng/dL
Men age greater than or equal to18 years.
Children are excluded because prostate cancer is not common in pediatric populations.
Women are not eligible because this disease occurs only in men.
- ECOG performance status 0-1.
Patients must have adequate organ and marrow function, and other laboratory parameters as defined below:
- hemoglobin greater than or equal to 9 g/dL
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SGPT) less than or equal to 3 X institutional upper limit of normal
- creatinine within normal institutional limits; OR,
- creatinine clearance greater than or equal to 30 mL/min/1.73 m2 for patients with creatinine levels above institutional normal (calculated via EGFR)
- Lesions within prostate must be detectable on MRI for biopsy.
- The effects of enzalutamide and abiraterone on the developing human fetus are unknown. For this reason and because androgen receptor antagonists as well as other therapeutic agents used in this trial are known to be teratogenic, male participants and their female partners of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence). Male participants should use a condom if having intercourse with a pregnant woman. Additionally, a condom plus another effective method of birth control is recommended during therapy and for 3 months after treatment for male participants having intercourse with a woman of reproductive potential. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately and her partner should inform the study team.
- Ability of subject to understand and the willingness to sign a written informed consent document.
- Willingness to adhere to protocol requirements (e.g., required biopsies).
- Willingness to travel to NIH for follow-up visits.
- Patients who are receiving any other investigational agents (in the past 28 days) or herbal medications (within 1 day prior to registration).
- Patients with evidence of distant metastatic disease beyond N1 (regional) lymph nodes on conventional imaging studies (e.g., CT, MRI or Bone Scan).
- Patients who have received any prior definitive therapy (ie: surgery, systemic treatment or radiation therapy) for prostate cancer.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to enzalutamide, abiraterone or other agents used in study.
- Clinically significant cardiac disease, e.g., New York Heart Association (NYHA) classes III-IV; uncontrolled angina, uncontrolled arrhythmia or uncontrolled hypertension (greater than or equal to 160/100 mmHg on two consecutive readings), myocardial infarction in the previous 6 months as confirmed by an electrocardiogram (ECG).
Contraindication to biopsy:
- Bleeding disorders for which a prostate biopsy would pose a bleeding risk
- PT/PTT greater than or equal to 1.5 times the upper limit of normal
- Artificial heart valve
Contraindication to MRI:
- Patients weighing more than the weight limit or unable to fit the scanner
- Allergy to MR contrast agent
- Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic device
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.
- HIV-positive patients on antiretroviral therapy are ineligible because of potential pharmacokinetic interactions with study drugs. However, patients with long-standing (>5 years) HIV on antiretroviral therapy > 1 month (undetectable HIV viral load and CD4 count > 150 cells/microliter) may be eligible if the PI determines no anticipated clinically significant drug-drug interactions.
- Patients undergoing active treatment for Hepatitis B or C infections.
- Patients who have taken medications that are strong inhibitors or inducers of CYP3A4 or PgP within 14 days prior to enrollment and need to remain on these medications.
- Other medications used for urinary symptoms including 5-alpha reductase inhibitors (finasteride and dutasteride) and alternative medications known to alter PSA (e.g., phytoestrogens and saw palmetto) cannot be taken while patients are receiving enzalutamide and abiraterone.
- Contraindication to steroid use.
- Patients with malignancy within the past 3 years for which study drugs or a prostatectomy is a contraindication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03860987
|Contact: Katherine O Lee-Wisdom, R.N.||(240) firstname.lastname@example.org|
|Contact: Fatima H Karzai, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Fatima H Karzai, M.D.||National Cancer Institute (NCI)|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
|First Posted:||March 4, 2019 Key Record Dates|
|Last Update Posted:||January 26, 2023|
|Last Verified:||January 23, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
|Time Frame:||Clinical data available during the study and indefinitely.@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active|
|Access Criteria:||Clinical data will be made available via subscription to BTRIS and with the permission of the study PI. @@@@@@Genomic data are made available via dbGaP through requests to the data custodians.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Genital Neoplasms, Male
Neoplasms by Site
Genital Diseases, Male
Male Urogenital Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal